相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data
Nikolaos Tsamandouras et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Model-Based Evaluation of the Impact of Formulation and Food Intake on the Complex Oral Absorption of Mavoglurant in Healthy Subjects
Thierry Wendling et al.
PHARMACEUTICAL RESEARCH (2015)
In vivo methods for drug absorption - Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects
Erik Sjogren et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Development of mavoglurant and its potential for the treatment of fragile X syndrome
Baltazar Gomez-Mancilla et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Human in Vivo Regional Intestinal Permeability: Importance for Pharmaceutical Drug Development
Hans Lennernas
MOLECULAR PHARMACEUTICS (2014)
Validation of an LC-MS/MS method for the quantitative determination of mavoglurant (AFQ056) in human plasma
Annamaria Jakab et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2013)
AFQ056 in Parkinson Patients With Levodopa-Induced Dyskinesia: 13-Week, Randomized, Dose-Finding Study
Fabrizio Stocchi et al.
MOVEMENT DISORDERS (2013)
Metabolism and Disposition of the Metabotropic Glutamate Receptor 5 Antagonist (mGluR5) Mavoglurant (AFQ056) in Healthy Subjects
Markus Walles et al.
DRUG METABOLISM AND DISPOSITION (2013)
Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis
Andrea L. Jorgensen et al.
PLOS ONE (2012)
AFQ056 Treatment of Levodopa-Induced Dyskinesias: Results of 2 Randomized Controlled Trials
Daniela Berg et al.
MOVEMENT DISORDERS (2011)
Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-The effect of diltiazem on the time-course of exposure to triazolam
Karen Rowland Yeo et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation Study
Ping Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
A method for robust model order reduction in pharmacokinetics
Aristides Dokoumetzidis et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2009)
Whole body physiologically-based pharmacokinetic models: their use in clinical drug development
Andrea N. Edginton et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Prediction of drug tissue to plasma concentration ratios using a measured volume of distribution in combination with lipophilicity
Rasmus Jansson et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Prediction of intestinal first-pass drug metabolism
Jiansong Yang et al.
CURRENT DRUG METABOLISM (2007)
Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs
Stefan Willmann et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
Whole-body physiologically based pharmacokinetic models
Ivan Nestorov
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2007)
Diazepam pharamacokinetics from preclinical to phase I using a bayesian population physiologically based pharmacokinetic model with informative prior distributions in winbugs
Ivelina Gueorguieva et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2006)
Structural identifiability of physiologically based pharmacokinetic models
JWT Yates
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2006)
Oral absorption of poorly water-soluble drugs: Computer simulation of fraction absorbed in humans from a miniscale dissolution test
Ryusuke Takano et al.
PHARMACEUTICAL RESEARCH (2006)
Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children
Trevor N. Johnson et al.
CLINICAL PHARMACOKINETICS (2006)
A mechanistic approach for the scaling of clearance in children
Andrea N. Edginton et al.
CLINICAL PHARMACOKINETICS (2006)
Development and evaluation of a generic physiologically based pharmacokinetic model for children
Andrea N. Edginton et al.
CLINICAL PHARMACOKINETICS (2006)
Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability
E. M. Howgate et al.
XENOBIOTICA (2006)
Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging
C Schiller et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Examination of 209 drugs for inhibition of cytochrome p450 2C8
RL Walsky et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible
DM Stresser et al.
DRUG METABOLISM AND DISPOSITION (2004)
The complex-step derivative approximation
JRRA Martins et al.
ACM TRANSACTIONS ON MATHEMATICAL SOFTWARE (2003)
Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs
DX Sun et al.
PHARMACEUTICAL RESEARCH (2002)
General solution for diffusion-controlled dissolution of spherical particles. 2. Evaluation of experimental data
JZ Wang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2002)
Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics
I Nestorov
TOXICOLOGY LETTERS (2001)
Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene
F Jonsson et al.
TOXICOLOGY (2001)
Regulation of intestinal blood flow
PJ Matheson et al.
JOURNAL OF SURGICAL RESEARCH (2000)
分享论文
